Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Diabetes and Vascular Disease Research
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Berhanu, P.
Right arrow Articles by Fleck, P. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berhanu, P.
Right arrow Articles by Fleck, P. R
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CHOLESTEROL
Medline Plus Health Information
*Diabetes
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy

Paulos Berhanu

Division of Endocrinology, Diabetes and Metabolism, Wayne State University School of Medicine, Detroit, MI, US

Mark S Kipnes

Diabetes and Glandular Disease Clinic, San Antonio, TX, US

Mehmood A Khan

Takeda Global Research & Development, Inc., Lincolnshire, IL, US

Alfonso T Perez

Takeda Global Research & Development, Inc., Lincolnshire, IL, US

Stuart F Kupfer

Takeda Global Research & Development, Inc., Lincolnshire, IL, US

Robert G Spanheimer

Takeda Global Research & Development, Inc., Lincolnshire, IL, US

Seleshi Demissie

Takeda Global Research & Development, Inc., Lincolnshire, IL, US

Penny R Fleck

Takeda Global Research & Development, Inc., Lincolnshire, IL, US

4The aim of this study was to evaluate changes in lipid profiles in patients with type 2 diabetes after treatment conversion from rosiglitazone to pioglitazone while maintaining stable statin and other lipid-altering therapies.

A total of 305 patients were enrolled in this open-label study. Patients had been taking stable dosages of rosiglitazone and statins for > 90 days. At baseline, patients discontinued rosiglitazone and started pioglitazone 30 mg/day, but continued statins and other lipid-altering therapies. The primary end point was change from baseline in fasting triglyceride levels.

At 17 weeks after treatment conversion, patients had significant reductions in triglycerides (-15.2%), total cholesterol (-9.0%), and low-density lipoprotein (LDL) particle concentration (-189 nmol/L), and increases in LDL cholesterol (+2.2%), high-density lipoprotein (HDL) cholesterol (+1.8%), and LDL particle diameter (+0.23 nm). In conclusion, after treatment conversion from rosiglitazone to pioglitazone while maintaining stable statin therapy, patients with type 2 diabetes had marked improvements in lipid profiles along with stable glycaemic control.

Key Words: lipids • apolipoproteins • LDL particles • statins • type 2 diabetes • thiazolidinediones

Diabetes and Vascular Disease Research, Vol. 3, No. 1, 39-44 (2006)
DOI: 10.3132/dvdr.2006.005
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
S. A. Kassem and I. Raz
Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No
Diabetes Care, November 1, 2009; 32(suppl_2): S337 - S341.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
W. Zhao, S. G. Thacker, J. B. Hodgin, H. Zhang, J. H. Wang, J. L. Park, A. Randolph, E. C. Somers, S. Pennathur, M. Kretzler, et al.
The Peroxisome Proliferator-Activated Receptor {gamma} Agonist Pioglitazone Improves Cardiometabolic Risk and Renal Inflammation in Murine Lupus
J. Immunol., August 15, 2009; 183(4): 2729 - 2740.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. K. McGuire and S. E. Inzucchi
New Drugs for the Treatment of Diabetes Mellitus: Part I: Thiazolidinediones and Their Evolving Cardiovascular Implications
Circulation, January 22, 2008; 117(3): 440 - 449.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. Erdmann, J. A. Dormandy, B. Charbonnel, M. Massi-Benedetti, I. K. Moules, A. M. Skene, and on behalf of the PROactive Investigators
The Effect of Pioglitazone on Recurrent Myocardial Infarction in 2,445 Patients With Type 2 Diabetes and Previous Myocardial Infarction: Results From the PROactive (PROactive 05) Study
J. Am. Coll. Cardiol., May 1, 2007; 49(17): 1772 - 1780.
[Abstract] [Full Text] [PDF]